| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
An orally active Amazonian plant extract (BIRM) inhibits prostate cancer growth and metastasis
|
Dandekar, Devendra S.
|
|
2003
|
52 |
Suppl 1 |
p. 59-66
|
article
|
| 2 |
A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion
|
Leguizamo, Jorge
|
|
2003
|
52 |
Suppl 1 |
p. 333-338
|
article
|
| 3 |
Clinical significance of the expression of estrogen receptors α and β for endocrine therapy of breast cancer
|
Iwase, Hirotaka
|
|
2003
|
52 |
Suppl 1 |
p. 34-38
|
article
|
| 4 |
Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial
|
Niho, Seiji
|
|
2003
|
52 |
Suppl 1 |
p. 19-24
|
article
|
| 5 |
Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells
|
Bouffard, David Y.
|
|
2003
|
52 |
Suppl 1 |
p. 497-506
|
article
|
| 6 |
Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer
|
Heslin, Martin J.
|
|
2003
|
52 |
Suppl 1 |
p. 399-404
|
article
|
| 7 |
Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma
|
Nakajima, Masahide
|
|
2003
|
52 |
Suppl 1 |
p. 319-324
|
article
|
| 8 |
Induction of TNF-α, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells
|
Niiya, Masami
|
|
2003
|
52 |
Suppl 1 |
p. 391-398
|
article
|
| 9 |
Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms
|
Senderowicz, Adrian M.
|
|
2003
|
52 |
Suppl 1 |
p. 61-73
|
article
|
| 10 |
Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics
|
Yamori, Takao
|
|
2003
|
52 |
Suppl 1 |
p. 74-79
|
article
|
| 11 |
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors
|
Peters, G. J.
|
|
2003
|
52 |
Suppl 1 |
p. 1-12
|
article
|
| 12 |
Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer
|
Oshita, Fumihiro
|
|
2003
|
52 |
Suppl 1 |
p. 73-78
|
article
|
| 13 |
Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer
|
Yamada, Yasuhide
|
|
2003
|
52 |
Suppl 1 |
p. 125-130
|
article
|
| 14 |
Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer
|
Haddad, Robert I.
|
|
2003
|
52 |
Suppl 1 |
p. 303-306
|
article
|
| 15 |
Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial
|
Santoso, Joseph T.
|
|
2003
|
52 |
Suppl 1 |
p. 13-18
|
article
|
| 16 |
Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1
|
Ali, Shadan
|
|
2003
|
52 |
Suppl 1 |
p. 235-246
|
article
|
| 17 |
Survival-signaling pathway as a promising target for cancer chemotherapy
|
Fujita, Naoya
|
|
2003
|
52 |
Suppl 1 |
p. 24-28
|
article
|
| 18 |
Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation
|
Peron, Karine
|
|
2003
|
52 |
Suppl 1 |
p. 270-276
|
article
|
| 19 |
The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones
|
Workman, Paul
|
|
2003
|
52 |
Suppl 1 |
p. 45-56
|
article
|
| 20 |
The role of DNA synthesis inhibition in the cytotoxicity of 2′,2′-difluoro-2′-deoxycytidine
|
Ostruszka, Leo J.
|
|
2003
|
52 |
Suppl 1 |
p. 325-332
|
article
|
Journal description